Table 1 HRMS detects sustained increases in monoclonal light chain before standard methods do.

From: Sensitive multiple myeloma disease monitoring by mass spectrometry

PID Arm BOR (INV) BOR cycle Clinical progression method by IMWG Progression cycle by IMWG Last cycle measured by data cut-off Sustained M-protein increase by HRMS Last cycle measured by HRMS Difference in cycles, HRMS vs standard methoda Notes
001 EPd VGPR C7 NA NA C26 ND C26   No documented progression
031 Pd VGPR C9 Plasmacytoma C24 C23 C20 C23 4 C24 was an assessment visit, not a treatment cycle. Progression by SPEP at assessment visit C25
044 EPd VGPR C4 UPEP C9 C9 C6 C9 3  
058 EPd CRb C25-C26c NA NA C27 ND C39   No documented progression
060 EPd VGPR C4 UPEP C18 C19 C7 C19 11  
084 EPd VGPR C9 Plasmacytoma C18 C17 C15 C17 3 No progression by SPEP/UPEP
087 Pd VGPR C2 sFLC C11 C15 C8 C15 3 No progression by SPEP/UPEP
097 Pd CRb C11 NA NA C24 ND C36   No documented progression
100 EPd CR C13 SPEP C22 C24 C14 C24 8  
101 Pd VGPR C10 sFLC C18 C19 ND C19   No progression by SPEP/UPEP
103 EPd sCR C5 NA NA C24 ND C28   No documented progression
109 EPd VGPR C14 NA NA C24 ND C35   No documented progression
116 EPd VGPR C8 NA NA C23 C14 C35 9 No documented progression
121 EPd CR C4 UPEP C15 C17 C8 C17 7  
122 Pd CRb C7 NA NA C22 C21 C31   No documented progression
133 EPd VGPR C10 NA NA C22 C31 C34   No documented progression
151 EPd VGPR C6 NA NA C20 C15 C25 5 No documented progression
  1. The time point (in treatment cycles) of patient relapse, as well as method used to determine clinical relapse, is shown together with the time point where a sustained increase in monoclonal light chain levels is detected by HRMS.
  2. PID patient identification, BOR best overall response, INV investigator, IMWG International Myeloma Working Group, HRMS high-resolution mass spectrometry.
  3. aAs determined by the date of data cut-off.
  4. bNo bone marrow available to confirm CR.
  5. cBOR documented between C25 and C26.